Class-action lawsuits against publicly traded companies, which ironically are meant to protect investors like me, have officially jumped the shark. That was the only conclusion I could come to after learning last week that one firm alone, Levi & Korsinsky, is suing not one, but three companies I invest in—Aegerion Pharmaceuticals (NASDAQ: [[ticker:AEGR]]), Sarepta Therapeutics … Continue reading “Supreme Court Should Scale Back Securities Class Actions”
Author: Brad Loncar
Brad Loncar is an individual investor.
For CytRx’s Insiders, What a Difference a Day Makes
CytRx (NASDAQ: [[ticker:CYTR]]) investors had a lot to be happy about last week. The good times came on Wednesday, Dec. 11, after the small cap biotech announced encouraging summary results from a mid-stage clinical trial of its doxorubicin conjugate, aldoxorubicin, in patients getting their initial treatment for soft tissue sarcoma. This announcement sent Los Angeles-based … Continue reading “For CytRx’s Insiders, What a Difference a Day Makes”
In Defense of Sarepta’s Chris Garabedian
Anyone who follows the biotechnology industry surely is aware of the setback Cambridge, MA-based Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) experienced this week after FDA changed their mind about the company’s ability to request early approval for its Duchenne Muscular Dystrophy drug, eteplirsen, on the basis of an encouraging Phase IIb study of 12 patients. However, the … Continue reading “In Defense of Sarepta’s Chris Garabedian”
SEC’s New Social Media Guidance: Sensible, Fair, Inevitable
Give the SEC a lot of credit…the headline they chose for their press release yesterday about public companies using social media could not have been more clear: “SEC Says Social Media OK for Company Announcements if Investors Are Alerted.” With those words, and a full report here, the commission has blessed the inevitable modernization of corporate … Continue reading “SEC’s New Social Media Guidance: Sensible, Fair, Inevitable”
SEC’s Action Against Hastings a Step Backwards
Last night, Netflix disclosed that the Securities and Exchange Commission, @sec_news if you want to follow them on Twitter, intends to institute a cease and desist proceeding and/or bring a civil injunction against Netflix and its CEO Reed Hastings for a posting he made on the social media website Facebook this summer. As an individual … Continue reading “SEC’s Action Against Hastings a Step Backwards”
The Case for Including Investors on Conference Calls
We are in the middle of a busy earnings season on Wall Street, which for an independent investor like me means listening to a lot of company conference calls. While that admittedly is not always the most exciting way to spend your days and evenings, I would like to relate a story about a novel … Continue reading “The Case for Including Investors on Conference Calls”
Good for Some, Good for All
The recent Facebook IPO has brought to the front pages an issue that many ordinary investors have been asking themselves for a long time: “Is the system fair?” In Facebook’s case, legitimate questions have arisen about why Morgan Stanley, Goldman Sachs, and J.P. Morgan, Facebook’s lead underwriters, all reduced their internal revenue estimates for that … Continue reading “Good for Some, Good for All”
An Open Letter to Dendreon’s Chairman
[Editor’s Note: This letter was sent today to Dendreon chairman Richard Brewer.] Dear Mr. Brewer: Just over five months ago I wrote to you expressing serious concerns about the composition of the board of directors and its oversight of Dendreon’s management. I appreciated the opportunity to discuss these views in person with management at company … Continue reading “An Open Letter to Dendreon’s Chairman”